Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy improves mood and energy
In plain terms: Will testosterone therapy fix low mood and energy?
Leans support Longevity & Aging 🔬 Includes disconfirming
Part of: 💊 Testosterone therapy (TRT)
RefutedContestedStrong support
consensus score 0.23
This is genuinely uncertain. The best large trials found only small-to-no effect on energy and vitality, and studies in men with actual clinical depression mostly found no antidepressant benefit beyond placebo. Some symptom scores improve modestly, but the 'T will restore your drive' promise outruns the evidence.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
8 support 3 contradict 3 tested null 3 mixed · 17 sources, 11 independent groups
What the evidence shows
TRT appears to give a small, inconsistent lift to mood and energy — a weak leaning-positive signal, not the transformation it's often sold as. The most rigorous large trials (the Testosterone Trials, TRAVERSE) found only small-to-null effects on vitality and fatigue, and randomized trials in men with diagnosed clinical depression generally found no antidepressant effect beyond placebo.
The evidence (23)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ichino K, Okui N, Ide H, Horie S 2026 · Cureus | n-of-1 | contradicts | low | Case report: 54-year-old man with MDD and low testosterone given TRT (8 monthly injections); perceived mood/energy benefit was limited and transient, and TRT was discontinued after symptoms recurred. |
| Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, Serrano V, Singh-Ospina N, Rodriguez-Gutierrez R, Salcido-Montenegro A, Benkhadra R, Prokop LJ, Bhasin S, Brito JP 2018 · J Clin Endocrinol Metab | meta-analysis | contradicts | moderate | Meta 4 RCTs (n=1779): NO significant effect on energy or mood versus placebo. |
| Chan J, Cunningham J, Cunningham C, Cunningham J, Cunningham C 2026 · European journal of obstetrics & gynecology and reproductive biology: X | observational | supports | low | Retrospective single-practice review of 78 menopausal women on testosterone pellet therapy; Menopause Rating Scale scores (which include mood/tiredness items) significantly improved across all 11 symptom categories. |
| Mok SF, Fennell C, Savkovic S, Turner L, Jayadev V, Conway A, Handelsman DJ 2020 · J Gerontol A Biol Sci Med Sci | RCT | contradicts | moderate | Double-blind placebo-controlled crossover, 45 men aged >=40 WITHOUT pathologic hypogonadism but with androgen-deficiency-like energy/sexual symptoms, 6 weeks of daily testosterone gel per phase. Raising testosterone to the young-male range 'produced no significant benefit more than placebo for energy' (visual-analog Lead Symptom Score, primary endpoint); only 1 of 22 quality-of-life indices improved, and in a masked choice phase men did not pick testosterone more often than placebo. No point estimate or trend toward benefit is reported in the abstract, so this is a clean null on the directional claim -> contradicts per CONVENTIONS §5. Indirect population: eugonadal men, short 6-week exposure. |
| Hubska J, Jaszczuk P, Betlejewska J, Bylińska N, Bobrowicz M, Rak-Makowska B, Ambroziak U 2026 · Front Endocrinol (Lausanne) | observational | supports | low | Single-patient uncontrolled open-label case report (not an n-of-1 trial - no randomisation, blinding, washout or rechallenge): 32-year-old woman with salt-wasting CAH and complete ACTH/DHEAS/testosterone suppression from chronic childhood glucocorticoid overtreatment. On compassionate-use low-dose IM testosterone she 'reported substantial improvement in muscle pain, strength, libido, and mood' within 3 months and 'sustained good overall well-being' at 10 years. All outcomes are patient-reported; the authors state validated questionnaires could not be reliably obtained. Population is female iatrogenic androgen deficiency, not male hypogonadism. |
| Amiaz R, Pope HG, Mahne T, Kelly JF, Brennan BP, Kanayama G, Weiser M, Hudson JI, Seidman SN 2011 · J Sex Marital Ther | RCT | tested-null | low | RCT (depressed men on SSRIs): improved sexual function but mood/depression not differentiated from placebo per protocol. |
| Canal de Velasco LM, González Flores JE, Morales Arteaga JL 2025 · Cureus | observational | supports | moderate | Narrative review of men aged 50+ synthesizing RCTs/cohorts/meta-analyses; reports TRT improves vitality along with sexual, musculoskeletal, and metabolic outcomes in men with baseline testosterone <300 ng/dL. |
| Elggren CW, Iverson CH, Morris MD, Cooper-Leavitt EF, Parker G, Richardson AW, Reynolds AP, Cortes PM, Bikman BT, Reynolds PR 2026 · Journal of personalized medicine | observational | supports | low | Retrospective survey of 332 women on TRT (telehealth) rated 8 symptom domains at a single post-treatment timepoint; energy/fatigue improved in 84.3%, depression in >65%, energy/fatigue and mood self-identified as top benefits. |
| Canal de Velasco LM, González Flores JE, Vargas L, Morales Arteaga JL 2026 · Cureus | RCT | supports | moderate | PRISMA systematic review of 11 RCTs (>600 men, ages 18-85) found testosterone therapy significantly improved depressive symptoms in treatment-resistant depression and cognition in older/hypogonadal men; global cognition and anxiety effects |
| Sato Y, Akagashi K, Tobe M, Haga K, Uchida K, Honma I, Hirobe M, Ishizaki J, Shimizu T, Watanabe K, Nakajima H 2026 · International journal of urology : official journal of the Japanese Urological Association | observational | supports | moderate | Real-world single-arm study of 227 Japanese men with late-onset hypogonadism symptoms given TRT + daily PDE5i; questionnaire scores for mood, vitality, and vigor significantly improved, with ~96% reporting some improvement. |
| Canal de Velasco LM, González Flores JE 2025 · Cureus | observational | supports | low | Narrative review of men aged 40-49 reports select cohorts showing improvements in mood, energy, vitality, and modest cognition with TRT, alongside metabolic and body-composition gains. |
| Seidman SN, Spatz E, Rizzo C, Roose SP 2001 · J Clin Psychiatry | RCT | tested-null | moderate | RCT (hypogonadal men with MDD): antidepressant effect not differentiated from placebo (HAM-D). |
| Chandra MS, Wang C, Gagliano-Jucá T, Gaikwad E, Shang YV, Pencina KM, Bhasin S 2026 · Endocr Pract | observational | supports | low | Retrospective cohort of 33 prostate cancer survivors (post-radiotherapy +/- ADT) given TRT; associated with improvements in fatigue, mood, and sexual symptoms alongside anemia correction. |
| Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials Investigators 2016 · N Engl J Med | RCT | mixed | high | Vitality Trial of the Testosterone Trials (NCT00799617): double-blind, placebo-controlled, minimization-allocated, intention-to-treat, 12 months of titrated testosterone gel vs placebo in men >=65y with mean serum testosterone <275 ng/dL, self-reported low vitality and FACIT-Fatigue <40; men with severe depression (PHQ-9 >=20) were excluded, so this is mood in NON-depressed older men. DENOMINATOR IS THE VITALITY TRIAL, NOT THE 790 HEADLINE: 236 testosterone / 238 placebo on the primary, 208/196 for SF-36 vitality, 229/234 for PANAS, 230/234 for PHQ-9. ENERGY HALF NULL ON ITS OWN PRIMARY: 'Among men enrolled in the Vitality Trial, testosterone treatment showed no significant benefit over placebo with respect to vitality, as determined by an increase of at least 4 points in the FACIT-Fatigue score (primary outcome) (odds ratio, 1.23; P = 0.30)'; the same responder outcome stayed null across all participants (OR 1.23, P=0.22), and continuous FACIT-Fatigue was +1.21 points, P=0.06, within the trial. MOOD HALF POSITIVE BUT TINY, ON UNADJUSTED SECONDARY OUTCOMES: 'the SF-36 vitality score (mean difference, 2.41 points; P = 0.03), the PANAS positive affect score (mean difference, 0.47 points; P = 0.04)', PANAS negative affect -0.49 (P<0.001) and PHQ-9 depression -0.72 (P=0.004) - with the authors' own ceiling on all of it: 'The effect sizes (the mean between-group differences in outcome divided by the baseline standard deviations) were all below 0.20.' Genuinely mixed on this claim's compound object. TWO CAVEATS THE OLD EXTRACT DROPPED: 'We analyzed the three trials as independent studies, without adjusting analyses of the primary outcomes for multiple comparisons' (nor within-trial primary vs secondary), and every all-participants figure is exploratory - 'The outcomes for all Testosterone Trials participants are exploratory outcomes.' Quality stays high on design: 705 of 790 completed, pattern-mixture and shared-random-effects sensitivity analyses for missing data, and AbbVie 'did not participate in the design or conduct of the trials or in the analysis, review, or reporting of the data'. |
| Nian Y, Ding M, Hu S, He H, Cheng S, Yi L, Li Y, Wang Y 2017 · Aging Male | meta-analysis | supports | moderate | Meta 5 RCTs (n=1212): reduced Aging Males' Symptom total and psychological/somatic/sexual subscales. |
| Walther A, Breidenstein J, Miller R 2019 · JAMA Psychiatry | meta-analysis | supports | moderate | Meta 27 RCTs (n=1890): significant reduction in depressive symptoms vs placebo (Hedges g=0.21, small); stronger at higher doses. |
| Bhasin S, Seidman S, Travison TG, Pencina KM, Lincoff AM, Nissen SE, Miller MG, Flevaris P, Li X, Wannemuehler KA, Pope HG 2024 · J Clin Endocrinol Metab | RCT | mixed | high | TRAVERSE depression substudy (n=5204): small significant improvements in mood/energy; no benefit in rigorously-defined dysthymia (underpowered). |
| Pinto da Costa Viana D, Jacobsen L, Gabriel LH, Lobo de Souza Correia E, da Maia Fernandes D, Nagel ML, Comin A 2025 · Cureus | observational | supports | low | Structured narrative review of 38 studies on subcutaneous testosterone pellets in women; observational cohorts reported improvements in mood and energy alongside sexual function, but findings limited by non-randomized design, lack of blindi |
| Matsumoto AM 2020 · J Gerontol A Biol Sci Med Sci | mechanism | mixed | low | T-Trials summary: slight improvement in mood/depressive symptoms and walking distance; no improvement in vitality or cognition. |
| Abadom MC, Nyong E, Hernandez BS, Saffati G, Parikh N, Khera M 2026 · Sex Med Rev | observational | supports | low | Narrative review: 'We conducted a narrative review of PubMed, Medline, and Google Scholar for articles published between 1980 and 2024.' Concludes 'TRT improves mood, energy, and libido in hypogonadal men'; no pooling. Review — zero weight. |
| Carvalho MS, Torres RC, Toniasso IM, Magalhães AO, Borges CM, Rocha EP, Kojima CA, Elias RM 2026 · Frontiers in endocrinology | observational | supports | low | Cross-sectional study of hemodialysis patients; among 16 hypogonadal men given testosterone supplementation, 66.7% showed improved ADAM questionnaire scores (which include mood/energy items), median score falling from 3 to 1. |
| Seidman SN, Roose SP 2005 · J Clin Psychopharmacol | RCT | tested-null | moderate | RCT: no significant between-group difference in HAM-D; mood improved similarly in T and placebo arms. |
| Cruickshank M, Hudson J, Hernández R, Aceves-Martins M, Quinton R, Gillies K, Aucott LS, Kennedy C, Manson P, Oliver N, Wu F, Bhattacharya S, Dhillo WS, Jayasena CN, Brazzelli M 2024 · Nat Med | meta-analysis | supports | moderate | IPD meta 35 trials: TRT improved quality of life; low mood improvement partly drove cost-effectiveness. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.